The European Commission has announced a €225 million investment aimed at accelerating the development of next-generation influenza vaccines capable of providing broader protection against multiple virus variants and adapting rapidly to emerging pandemic strains.
The funding will support the advancement of innovative flu vaccines designed to be easier to administer, including nasal sprays, oral formulations, and skin patches. These alternative delivery methods are expected to improve patient access and compliance, particularly among vulnerable and underserved populations, while also enabling faster and more flexible responses during public health emergencies.
Influenza viruses are known for their rapid mutation, requiring vaccines to be regularly updated to match circulating strains. By investing in new technologies and expanding the clinical pipeline, the Commission aims to ensure Europe is better prepared for seasonal outbreaks and potential pandemics. The initiative seeks to move promising vaccine candidates through full clinical development and toward market authorisation, helping bridge the gap between laboratory innovation and widespread public use.
The contracts signed under the program will run for 98 months and will cover clinical trials through to regulatory approval. This marks the first time the Commission is deploying a pre-commercial procurement mechanism to advance vaccine candidates through clinical development. The approach is designed to ensure that supported products meet strict standards for safety, quality, and efficacy, while also providing public backing for high-risk innovations that might otherwise struggle to secure sufficient private investment.
Officials say the initiative will not only enhance Europe’s pandemic preparedness but also expand vaccine manufacturing capacity and strengthen the continent’s pharmaceutical ecosystem. By widening the range of vaccine technologies in development, the EU aims to increase the likelihood that novel solutions reach national immunization programs more quickly.
Hadja Lahbib, European Commissioner for Equality, Preparedness, and Crisis Management, described the €225 million package as the largest EU investment dedicated to accelerating access to innovative medical countermeasures. She emphasized that innovation is central to preparedness and noted that the funding will help unlock cutting-edge vaccine technologies and diversify administration methods.
Beyond immediate public health goals, the investment is also intended to reinforce Europe’s competitiveness in pharmaceutical research and production. By strengthening both scientific capability and industrial readiness, the Commission aims to ensure that Europe — and its global partners — are better equipped to respond swiftly and effectively to future influenza threats.